Subscribe
Rosemarie Mosteller / Shutterstock.com
26 June 2025NewsAmericasLiz Hockley

BMS faces fresh lawsuit over alleged cancer drug monopoly

Insurance company Cigna claims Bristol Myers Squibb may have caused overpayments of ‘billions’ of dollars after allegedly delaying market entry of generic Pomalyst | Lawsuit follows dismissal of antitrust suit against pharma giant over same drug.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
BMS notches legal win and FDA nod
10 April 2025   Pharma giant dodges threat as US judge dismisses monopoly claims over its blockbuster cancer drug | FDA approves new treatment combo for advanced colorectal cancer.


Editor's picks

A step too far? Why Stewart’s approach is dividing opinion
Americas
A step too far? Why Stewart’s approach is dividing opinion
24 June 2025

Editor's picks

Americas
A step too far? Why Stewart’s approach is dividing opinion
24 June 2025
Europe
UPC confirms permanent injunction against Curio in 10x tech dispute
17 June 2025
Americas
LSPN: In-house ‘chess game’ is the same, but the rules have changed
9 May 2025
Americas
Life sciences leaders recognised at LSPN Awards USA 2025
8 May 2025
Americas
LSPN: Counsel grapple with AI’s impact on training and critical thinking
8 May 2025
Americas
LSPN: Using ‘the patentee’s friend’ in Section 112 claims
6 May 2025

More on this story

Americas
BMS notches legal win and FDA nod
10 April 2025   Pharma giant dodges threat as US judge dismisses monopoly claims over its blockbuster cancer drug | FDA approves new treatment combo for advanced colorectal cancer.

More on this story

Americas
BMS notches legal win and FDA nod
10 April 2025   Pharma giant dodges threat as US judge dismisses monopoly claims over its blockbuster cancer drug | FDA approves new treatment combo for advanced colorectal cancer.

More features

Broad Institute wins appeal to restore CRISPR patent in Europe
WATCH: Synergy in science—navigating the landscape of pharmaceutical collaborations
Boies Schiller Flexner adds three-strong litigation team
AstraZeneca forced to clarify deal terms in row with university
Novartis loses cancer drug patent following Teva challenge at EPO
A step too far? Why Stewart’s approach is dividing opinion
WATCH: Section 112—Where has the dust settled?
UPC rejects Alexion’s rehearing bid in spat with Amgen and Samsung